Amarin | AMRN - Ebit

Stock Price
14.31
Daily Change
-0.28 -1.92%
Monthly
-2.52%
Yearly
37.20%
Q2 Forecast
13.88

Amarin reported $-2.26M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -2.26M 564K Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.06B 530M Dec/2025